Groll AH - Search Results

1

Treatment of fungal infections in neutropenic children.

Lehrnbecher T, Groll AH, Chanock SJ. Lehrnbecher T, et al. Among authors: groll ah. Curr Opin Pediatr. 1999 Feb;11(1):47-55. doi: 10.1097/00008480-199902000-00010. Curr Opin Pediatr. 1999. PMID: 10084084 Review.

2

[Progress in prevention and therapy of infectious complications in children and adolescents with neoplastic diseases].

Groll AH, Müller FM. Groll AH, et al. Klin Padiatr. 1998 May-Jun;210(3):106-14. doi: 10.1055/s-2008-1043860. Klin Padiatr. 1998. PMID: 9629543 Review. German.

3

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.

Groll AH, Müller FM, Piscitelli SC, Walsh TJ. Groll AH, et al. Klin Padiatr. 1998 Jul-Aug;210(4):264-73. doi: 10.1055/s-2008-1043890. Klin Padiatr. 1998. PMID: 9743964 Review.

4

Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Petraitis V, Petraitiene R, Groll AH, Bell A, Callender DP, Sein T, Schaufele RL, McMillian CL, Bacher J, Walsh TJ. Petraitis V, et al. Among authors: groll ah. Antimicrob Agents Chemother. 1998 Nov;42(11):2898-905. doi: 10.1128/AAC.42.11.2898. Antimicrob Agents Chemother. 1998. PMID: 9797223 Free PMC article.

5

Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus.

Müller FM, Groll AH, Walsh TJ. Müller FM, et al. Among authors: groll ah. Eur J Pediatr. 1999 Mar;158(3):187-99. doi: 10.1007/s004310051047. Eur J Pediatr. 1999. PMID: 10094436 Review.

6

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.

Groll AH, Gonzalez CE, Giri N, Kligys K, Love W, Peter J, Feuerstein E, Bacher J, Piscitelli SC, Walsh TJ. Groll AH, et al. J Antimicrob Chemother. 1999 Jan;43(1):95-103. doi: 10.1093/jac/43.1.95. J Antimicrob Chemother. 1999. PMID: 10381106

7

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

Chiou CC, Groll AH, Walsh TJ. Chiou CC, et al. Among authors: groll ah. Oncologist. 2000;5(2):120-35. doi: 10.1634/theoncologist.5-2-120. Oncologist. 2000. PMID: 10794803 Free article. Review.

8

Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients.

Walsh TJ, Roden M, Roilides E, Groll A. Walsh TJ, et al. Int J Antimicrob Agents. 2000 Oct;16(2):151-6. doi: 10.1016/s0924-8579(00)00242-9. Int J Antimicrob Agents. 2000. PMID: 11053799 Review.

9

New targets and delivery systems for antifungal therapy.

Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, Odds FC. Walsh TJ, et al. Among authors: groll ah. Med Mycol. 2000;38 Suppl 1:335-47. Med Mycol. 2000. PMID: 11204162 Review.

10

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century.

Walsh TJ, Groll AH. Walsh TJ, et al. Among authors: groll ah. Transpl Infect Dis. 1999 Dec;1(4):247-61. doi: 10.1034/j.1399-3062.1999.010404.x. Transpl Infect Dis. 1999. PMID: 11428996 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters